contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


boehringer-ingelheim-advances-next-generation-triple-agonist-peptide-for-the-treatment-of-obesity-into-mid-stage-development

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Gubra er en medicinalvirksomhed. Virksomhedens aktiviteter er fokuseret på de tidlige stadier af lægemiddeludvikling. De udfører hovedsageligt forskning og udvikling inden for stofskifte- og fibrotiske sygdomme.Virksomhedens produktportefølje omfatter flere brands og lægemidler, og aktiviteterne foregår på globalt plan med den største tilstedeværelse i Nordamerika og Norden. Hovedkontoret ligger i Hørsholm, Danmark.

Gubra

· Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further developmentGubra partner Boehringer Ingelheim today announced...

<div class="mfn-preamble"><p><strong>· Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further development</strong></p></div><div class="mfn-body"><p>Gubra partner Boehringer Ingelheim today announced the advancement of BI 3034701, its long‑acting potential first-in-class triple‑agonist peptide, in development for the treatment of obesity. This milestone reflects Boehringer’s strategy to address the global burden of obesity and its interconnected cardiovascular, renal, metabolic (CRM) complications.</p><p>“We are very pleased to see Boehringer Ingelheim advancing this first-in-class triple-agonist to the next phase of clinical development. It builds on our joint ambition to develop novel assets for the treatment of obesity and related diseases”, said Markus Rohrwild, CEO of Gubra.</p><p>The unmet medical need is high and more than one billion people worldwide live with obesity, a complex, chronic disease associated with heightened risk of liver, cardiovascular, renal and metabolic complications.</p><p>Progression follows the completion of a randomized, placebo‑controlled Phase I study in healthy volunteers and people with overweight/obesity, where BI 3034701 demonstrated a favorable safety and tolerability profile and showed encouraging weight‑loss.</p><p>BI 3034701 was developed in cooperation with Gubra. Boehringer Ingelheim is solely responsible for further development and global commercialization of BI 3034701. The progression of this asset further expands Boehringer Ingelheim’s patient‑centric CRM pipeline portfolio.</p><p>As part of the license agreement, Gubra is entitled to receive potential success-based development, regulatory and commercialization milestones and royalties.</p></div><div class="mfn-footer mfn-contacts mfn-cffe77846134"><p><strong class="mfn-heading-1">Contacts at Gubra</strong><br>Media: Sofia Pitt Boserup (<a rel="noopener" href="mailto:sbo@gubra.dk">sbo@gubra.dk</a>, +45 4188 9586)<br>Investors: Kristian Borbos (<a rel="noopener" href="mailto:kbo@gubra.dk">kbo@gubra.dk</a>, +45 3080 8035) and Emma Jappe Lange (<a rel="noopener" href="mailto:ejl@gubra.dk">ejl@gubra.dk</a>, +45 5361 6755)</p></div><div class="mfn-footer mfn-about mfn-a42358512560"><p><strong class="mfn-heading-1">About Gubra</strong><br>Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in two main business units – Biotech (D&amp;P) and CRO services. The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&amp;D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around EUR 350 million) in the first 9 months of 2025. See <a rel="noopener" href="http://www.gubra.dk">www.gubra.dk</a> for more information.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-12-08 08:00 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/0614eea9-57f1-4f2a-b4de-8cf9b89a5d46/boehringer-ingelheim-advances-next-generation-triple-agonist-peptide-for-the-treatment-of-obesity-into-mid-stage-development.pdf" class="mfn-generated mfn-primary">Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development</a></p></div>

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development